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Abstract There are ethical concerns regarding the per-
formance of biopsies in patients for research purposes. We
examined our single-institution experience regarding
acceptance, safety, and success rate with research biopsies
in patients with breast cancer. Among patients with data
from paired samples, receptor status agreement between
primary and metastatic samples was examined, either on
first recurrence or after progression on one or more lines of
therapy. An IRB-approved prospective study at the Dana-
Farber Cancer Institute collects research biopsies as addi-
tional passes at the time of a clinical biopsy (AB, additional
biopsy) or as a separate procedure for banking purposes
(RPOB, research purposes only biopsy). Biopsies are not
linked to a specific therapeutic or correlative trial. Grade
2–5 adverse events are prospectively collected. 151
patients were included in the analytic cohort (total proce-
dures = 161); 80.8 % underwent AB, 17.2 % underwent
RPOB, and 2.0 % underwent both AB and RPOB. Most
patients were white (88.7 %) with a performance status of
0–1 (94.0 %). 96.0 % of patients underwent a biopsy in the
setting of known or suspected metastatic disease. Receptor
status between primary cancer and recurrent research
biopsies differed in 43.2 % of patients with available data
(18.8 % among patients who underwent the research
biopsy before any systemic treatment, 48.1 % after treat-
ment). Tissue was successfully collected in 92.3 % of
patients undergoing AB and 100 % patients undergoing
RPOB. Only three (2.0 %) patients had adverse events
Cgrade-2: one grade-2 pain; one grade-2 pneumothorax;
and one grade-3 pain. Our experience suggests research
biopsies can be performed safely with a high rate of suc-
cessful tissue collection. Consistent with previous reports
we found a high rate of discordance between primary and
metastatic samples, which was even higher among treated
patients. This supports continued efforts to study tissue
samples at multiple points in a patient’s disease course.
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Introduction
Research biopsies allow tumor tissue to be examined at
several time-points in the disease continuum and thus
provide important insights on biologic pathways, prog-
nostic, or predictive biomarkers, and new therapeutic tar-
gets. However, since there are risks associated with a
biopsy procedure and no direct benefit to participating
patients, there is active debate concerning the ethics of this
element of oncologic research [1–3].
Despite the risks, recent inquiries suggest that patients
are willing to undergo biopsies for research purposes only
[2, 4–6]. Tumor biopsies of patients enrolled in clinical
trials have become more common, and data on safety,
acceptance, and feasibility of invasive procedures in this
context is emerging [2, 4, 5, 7–13]. Most studies suggest
that research biopsies are a safe procedure, with a
0.8–1.4 % major complication rate. Risks do increase for
intrathoracic biopsies, however, with a reported major
complication rate of 2.4 % [11, 12]. However, very limited
data exists on the feasibility and safety of research biopsies
performed outside of therapeutic trials.
In this analysis, we examined our experience regarding
acceptance, safety, and success rate of research biopsies in
breast cancer patients outside of a therapeutic or transla-
tional trial. We also examined the agreement rate between
estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2) among
metastatic patients with paired samples, either on first
recurrence or after progression through one or more lines
of therapy.
Subjects and methods
An ongoing, Institutional Review Board (IRB)-approved,
prospective study at the Dana-Farber Cancer Institute
(DFCI) allows patients with breast cancer who are not
enrolled in a trial to undergo biopsies with the single aim of
banking tissue for future undetermined research. Initially,
this was limited to patients with metastatic breast cancer,
but was later amended to include breast cancer patients
with early stage disease who had intact primaries. We
examined our experience regarding the success rate and
safety profile of research biopsies in these patients.
Patients enrolled between January 1, 2006 and Decem-
ber 31, 2012 belonged to one of two cohorts: Cohort 1:
patients undergoing clinically-indicated biopsies during
which research biopsy specimens were obtained via addi-
tional passes; Cohort 2: patients undergoing biopsies for
research purposes only. Except for skin biopsies, all pro-
cedures were performed under ultrasound or computed
tomography (CT)-guidance by interventional radiologists.
The needle gauge used to collect tissue is between 16 and
20 gauge for core biopsies, or 22 gauge for fine needle
aspirates (FNA). The size of the needle used is left to the
clinical discretion of the radiologist. While the protocol
calls for a goal of 3–6 core samples, or three FNAs, to be
collected, ultimately the radiologist may suspend the pro-
cedure or not collect the full amount if he/she deems it
unsafe for the patient.
Complication risks were reviewed as part of informed
consent.
In the consent form, risks were labeled as common
(more likely) and rare (less likely). Overall, common risks
included local discomfort and minor bleeding, and rare
risks included moderate or major bleeding, need for blood
transfusion, hospitalization due to bleeding or other com-
plications, infection, damage to nearby organs, allergic
reaction to the numbing medicine. Specific language for
breast, lymph node, skin or chest wall, bone, liver, lung,
pleural fluid, or ascites fluid biopsies was incorporated in
the consent.
It was also stated that taking part in this research study is
not intended to have a direct impact on patient’s health.
The consent clarifies that the information learned from this
research study has the potential to help the oncology
community to learn more about changes that may occur in
tumors and to understand the effects of future treatments
for breast cancer.
It is specified in the consent process that no return of
research results is anticipated.
Grade 2–5 adverse events (AEs), according to NCI
CTCAE Version 4.0, were prospectively collected. Addi-
tionally, the electronic medical records were reviewed for
completeness of AE reporting.
We used the following variables in this analysis: date of
diagnosis and recurrence; age at time of biopsy; race;
performance status [14]; Charlson co-morbidity score [15];
subtype defined by ER status, PR status, and HER2 status
[tumor subtype was classified as hormone receptor (HR)?
(ER? and/or PR? and HER2-), HER2? (HER2?, any
HR), or triple negative (ER-/PR-/HER2-)]; context of
the biopsy (early breast cancer or metastatic/recurrent
disease); anti-cancer treatment before biopsy; date of
biopsy, location of biopsy; type of biopsy; AEs; success
rate. Successful biopsy was defined as one in which a
research specimen was collected and banked. Among
patients with data from paired samples, (primary and
recurrent research biopsies), agreement (yes or no) between
ER, PR, and HER2 status was tabulated and inter-rater
agreement between ER, PR, and HER2 was calculated
[simple kappa coefficients and asymptotic standard error
(ASE)]. The agreement was performed among the entire
cohort, as well as the patients that underwent research
biopsies before and after systemic treatment.
204 Breast Cancer Res Treat (2013) 142:203–209
123
Results
158 patients consented to the study; three withdrew consent
and 4 did not have biopsies. 151 patients were included in
the analytic cohort, with nine patients having multiple
biopsies on the protocol (total biopsies performed = 161).
80.8 % performed biopsies in Cohort 1, 17.2 % in Cohort
2, and 2.0 % in both Cohort 1 and 2 (Fig. 1).
The clinical and treatment characteristics of the study
population are presented in Table 1. Median age at time of
research biopsy was 52.0 years (24.7–82.6). Most patients
were white (88.7 %) with a performance status of 0–1
(94.0 %) and with a co-morbidity score of 0–1 (88.1 %).
39.7 % of biopsies were performed at time of diagnosis or
first recurrence. A majority of patients (96.0 %) underwent
a biopsy in the setting of known or suspected metastatic
disease. Tumor subtype distribution was as following:
43.7 % HR ? HER2-, 31.1 % HER2?, and 25.2 % triple
negative. In 81.5 % of cases patients had received prior
anti-cancer therapy at the time of the research biopsy.
Research biopsies were successfully performed in 120
cases of Cohort 1 (92.3 % of the 130 performed in this
cohort) and in 31 cases (100 %) of Cohort 2. In Cohort 1,
research samples were not collected successfully in ten
patients. For nine of these patients, the clinical samples had
insufficient tumor tissue, leading to the forfeit of banked
tissue for clinical purposes. A biopsy procedure was sus-
pended for one patient due to severe pain (Fig. 2).
The most common sites of biopsy were liver (37.9 %,
n = 61), skin (24.2 %, n = 39), and breast (18.0 %, n = 29).
Lung was uncommon and only biopsied by fine-needle aspi-
ration for patients in cohort 1 (2.5 %, n = 4). Three patients in
Fig. 1 Flow diagram of patient
population. Note: Total number
of biopsies performed in Cohort
1: 130, total number of biopsies




Table 1 Baseline characteristics at time of biopsy
N %
Age at biopsy (median, min–max) 52.0 (24.7–82.6)
Race
White 134 88.7















Early breast cancer 6 4.0







HR hormone receptor, HER2 human epidermal growth factor receptor 2
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Cohort 1 experienced AEs Cgrade-2: one grade-2 pain; one
grade-2 pneumothorax; and one grade-3 pain. No deaths were
attributable to research biopsies (Table 2).
Among patients with available data on their primary
tumors, ER status changed (N = 94, positive to negative,
or vice versa) in 18.1 % of patients; PR status changed
(N = 95, positive to negative, or vice versa) in 27.4 % of
patients; HER2 status changed (N = 94, positive to nega-
tive test) in 9.6 % of patients, six out of these nine patients
had at least one equivocal result. Among cases with dis-
cordance in the receptor status, in 86.5 % of cases the
receptors changed from a positive result to a negative one,
and in 13.5 % from a negative to a positive result
(Table 3).
Overall, there was a 43.2 % rate of any discordance
between primary sample receptor status and later research
biopsy tissue receptor status among all patients with
available data, with a 18.8 % rate of discordance among
patients who underwent the research biopsy before any
systemic treatment. Among patients who underwent the
research biopsy after treatment there was a 48.1 % rate of
any discordance.
Fig. 2 Success rate of biopsies per cohort* (N = 161) and reasons for failure. Note: N, number; b 9 s, biopsies; * successful biopsy, biopsy in
which a research specimen was collected and banked














% Grade Event Cohort Context of
biopsy
Chest wall
Breast 29 17 12 18.0 0 0
Lymph node 11 11 0 6.8 0 0
Skin 39 24 15 24.2 1 2.6 3 Pain 1 Progression
Other 1 1 0 0.6 0 0
Intra-thoracic
Lung 4 4 0 2.5 1 25.0 2 Pneumothorax 1 Diagnosis
Pleura/
pericardium
3 3 1 1.9 0 0
Mediastinum 1 1 0 0.6 0 0
Intra-abdominal
Liver 61 58 3 37.9 1 1.6 2 Pain 1 Recurrence
Soft tissue 5 5 0 3.1 0 0
Bone 7 7 0 4.3 0 0
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Discussion
This prospective study of patients with breast cancer sug-
gests that many patients are willing to undergo research
biopsies, with the single aim of banking tissue for future
undetermined research, even outside the context of a
therapeutic trial. Consistent with a recent survey study,
which indicated a higher willingness of metastatic breast
cancer patients to undergo additional passes at the time of a
clinically indicated biopsy compared to a research-only
biopsy, only 19.2 % (n = 29) of patients consented to a
research-only procedure [6]. However, it is notable that
125 patients (82.8 %) consented to an additional pass at the
time of a clinically indicated biopsy. Building on this
approach may increase the number of patients from whom
research biopsies may be obtained in a way that is
acceptable to patients and providers. In addition, support-
ing continued efforts to study tissue samples at multiple
points in a patient’s disease course we found a high rate of
discordance between primary and metastatic samples,
which was even higher among treated patients.
Available data suggest low rates of complication related
to research biopsies [8–12]. In a recent report of 745
research biopsies in 576 patients, overall and major com-
plications rates were 5.2 and 0.8 %, respectively. However,
the complication rate for intrathoracic biopsies was higher
(17.1 % overall; 2.4 % major complication) [12]. Our
results are consistent with these findings, with rare (1.9 %)
Cgrade-2 AEs overall, but one of eight (12.5 %) intratho-
racic biopsies was complicated by grade-2 pneumothorax.
When considering which patients to enroll for research
biopsies, we consider the safety of the patient first and
work closely with interventional radiology to identify
lesions that can be approached without undue risk. Because
of the higher complication rates reported from intrathoracic
sites, lung masses are targeted only in selected cases.
A prior study has suggested cancer patients consider the
risk from a research biopsy of a ‘‘major complication’’ up
to 20–25 % to be acceptable. Medical oncologists and IRB
personnel surveyed in the same study found a lower rate of
1–2 % risk of major complications acceptable [13]. Nota-
bly, overall, with the exception of biopsies targeting
intrathoracic sites, the complication rate in our study was
within the threshold deemed acceptable by medical pro-
fessionals. For intrathoracic biopsies although the sample
size was small, our results suggest that this may be
Table 3 Agreement between ER, PR and HER2 status from primary and recurrent samples
ER status K PR status K HER2 Status K
(ASE) (ASE) (ASE)
Agreement between HR and HER2 status from primary and recurrent research samples
Total (N) 94 95 94
Agreement, N (%)
Yes 77 (81.9) 0.628 69 (72.6) 0.440 85 (90.4) 0.784
No 17 (18.1) (0.079) 26 (27.4) (0.086) 9 (9.6) (0.067)
? to - 14 (14.9) 22 (23.2) 9 (9.6)
- to ? 3 (3.2) 4 (4.2) 0 (0)
Agreement before any treatment
Total (N) 16 16 16
Agreement, N (%)
Yes 15 (93.7) 0.875 (0.120) 13 (81.3) 0.586 (0.211) 15 (93.7) 0.875 (0.120)
No 1 (6.3) 3 (18.8) 1 (6.3)
? to - 1 (6.3) 2 (12.5) 1 (6.3)
- to ? 0 (0) 1 (6.3) 0 (0)
Agreement after treatment
Total (N) 78 79 78
Agreement, N (%)
Yes 62 (79.5) 0.569 (0.092) 56 (70.9) 0.414 (0.093) 70 (89.7) 0.750 (0.081)
No 16 (20.5) 23 (29.1) 8 (10.3)
? to - 13 (16.7) 20 (25.3) 8 (10.3)
- to ? 3 (3.8) 3 (3.8) 0 (0)
Data was not available in a limited number of samples due to: (1) unknown information in the metastatic setting, (2) research biopsy performed at
time of diagnosis. ? to -: change from positive to negative marker; - to ?: change from negative to positive marker
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor 2
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associated with a higher risk, and thus should not be pre-
ferred targets, particularly for research only biopsies.
Up to this point, the quantification of the breast cancer
biopsy risks is mainly driven by extrapolation from data
not focused on breast cancer [8–12]. Therefore, our study
provides additional information to help the medical com-
munity better quantify the risks of breast cancer research
biopsies, This allows us to update the consent forms of
ongoing studies and to inform future studies aiming to
collect tissue from breast cancer patients .
Although not impacting directly patient care, research
biopsies may provide new insights on biologic pathways,
prognostic or predictive biomarkers, and help to identify
new targets for therapeutics. Our analyses of discordance
of receptor status between the primary and metastatic site
are concordant with this concept.
Consistent with previous reports, among the overall
cohort, we found a 43.2 % rate of any discordance between
ER, PR, and HER2 receptor status in primary and recurrent
research biopsies. Furthermore, we found a lower discor-
dance rate among patients who did not receive prior anti-
cancer therapy versus patients who were previously treated.
These data are consistent with the existence of clonal
selection associated with therapy as a mechanism that con-
tributes to discordance between paired samples. They also
support the continued efforts to study tissue samples at
multiple points in a patient’s disease course [16]. However, it
is important to stress that most of the changes occurred from
a positive to a negative result, which carries fewer thera-
peutic implications than the reverse.
While the ethical questions surrounding research biopsies
can be challenging, major insights have been gained into
tumor biology as a result of studies of tumor tissue in multiple
settings [17]. Many scenarios can be scientifically informative
but not linked to clinically indicated biopsies; for example,
biopsies at the time of progressive disease in patients who
have had an extreme response to a targeted agent [18]. Putting
this trial in the context of the seven Emanuel [19] ethical
requirements for scientific research, a prospective cohort
study with a cohort of research-only biopsies can fulfill the
first two requirements of having value and scientific validity.
It can also be conducted to assure fair subject selection,
respect for enrolled subjects and under an independent review
process, meeting another three requirements. The challenge of
this particular protocol is to assure that the risks, although
more than minimal, are minimized to create a favorable risk–
benefit ratio and that during the informed consent process,
patients are educated about the actual risks and therapeutic
misconception of donating research tissue is eliminated.
The presented study has limitations. Patients were accrued
at a single academic medical center, perhaps narrowing the
ability to generalize results. Additionally, data on approach
and decline rates to this protocol are not available, hindering
understanding of both patient and physician attitudes toward
collecting tissue for future research projects. The success rate
of collecting tissue was used as a surrogate of evaluable tissue;
however, as a majority of samples have not undergone tissue
analysis, the rate of successful tissue utilization is currently
undetermined. Previous studies have estimated approxi-
mately 80 % of biopsy samples are usable for correlative
studies [10]; therefore, it is conceivable that the majority of
samples will be useful. We also did not conduct central
pathology review of the tumor samples to analyze discordance
in ER, PR, and HER2 receptor status between primary and
metastatic samples. Finally, although we know that three
patients in Cohort 1 experienced AEs Cgrade-2, we are not
able to assess if the complications were directly associated
with the clinically indicated biopsy or with the additional pass
performed for research purposes.
Conclusions
Progress in breast cancer research requires a strong part-
nership between researchers and patients. Maintaining the
careful balance between patients’ safety and understanding
of risks, as well as researchers’ necessity for tissue collec-
tion, is essential to ensuring advancement in the field [18].
Our data suggest that breast cancer patients are willing to
undergo research biopsies, including in the metastatic set-
ting, particularly when performed as extra passes at the time
of a clinically indicated biopsy. We have observed a high
rate of successful tissue collection, with an acceptable safety
profile. However, additional data are needed to fully quantify
the risks and to demonstrate the scientific value of these
procedures. Finally, we found a high rate of discordance
between primary and metastatic samples especially among
treated patients. This supports continued efforts to study
tissue samples at multiple points in a patient’s disease
course.
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